Herceptin
versus the new tyrosine kinase inhibitors
Interview
with Neil Love, MD from Breast Cancer Update for Medical Oncologists,
Program 5 2000
Play
Audio Below:
Herceptin, of course, is a monoclonal antibody, and what Herceptin
does is to effect the external membrane domain. The new tyrosine
kinase inhibitors, as a group, will be effecting the internal membrane
domain portion. I think one of the interesting research questions
going forward is whether or not one is better off effecting the
cascade externally or internally – what one is better off attacking.
Certainly from an expense and convenience stand point the tyrosine
kinase inhibitors, the internal membrane inhibitors, may have it
over the external membrane ones, such as Herceptin. In that they’re
likely to be oral medications – many of them – they’re
likely to be much less expensive to produce. Now, whether or not
they’ll be more efficacious, I think however, is going to represent
the really interesting question going forward.
Biological
rationale for HER2/neu (c-erbB2) as a target for monoclonal antibody
therapy [Review]. Pegram, M. and Slamon, D Seminars in Oncology.
27(5 Suppl 9):13-19, 2000 Oct.
In
process Current and planned clinical trials with trastuzumab (Herceptin)
[Review]. Baselga, J. Seminars in Oncology. 27(5 Suppl 9):27-32, 2000
Oct. In process
Clinical
trials of single-agent trastuzumab (Herceptin) [Review]. Seminars in Oncology. 27(5 Suppl 9):20-26, 2000 Oct. In proces
Biological
rationale for HER2/neu (c-erbB2) as a target for monoclonal antibody
therapy [Review].
Pegram, M. and Slamon, D Seminars in Oncology. 27(5 Suppl 9):13-19,
2000 Oct.
In process
The use of HER2 testing in the management of breast cancer [Review]. Ravdin,
P. Seminars in Oncology. 27(5 Suppl 9):33-42, 2000 Oct. In process
